High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Heart ◽  
2015 ◽  
Vol 101 (5) ◽  
pp. 356-362 ◽  
Author(s):  
Robert M Stoekenbroek ◽  
S Matthijs Boekholdt ◽  
Rana Fayyad ◽  
Rachel Laskey ◽  
Matti J Tikkanen ◽  
...  
Keyword(s):  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
High Dose ◽  
Moderate Dose ◽  
Peripheral Arterial

An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment

2021 ◽  
Vol 9 (10) ◽  
pp. 2428-2435
Author(s):  
Tingchao Zhang ◽  
Gaoyang Guo ◽  
Li Yang ◽  
Yunbing Wang
Keyword(s):  
Peripheral Arterial Disease ◽  
Therapeutic Effect ◽  
Arterial Disease ◽  
High Dose ◽  
Swine Model ◽  
Disease Treatment ◽  
Ultralow Dose ◽  
Peripheral Arterial

In this paper, an ultralow dose paclitaxel-coated balloon was developed. Benefiting from the unique design of the meglumine matrix and outer protective sheath, its therapeutic effect was comparable to those of commercial high-dose counterparts in the swine model.

scholarly journals High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD

2008 ◽  
Vol 99 (01) ◽  
pp. 182-189 ◽  
Author(s):  
Roger Simon ◽  
Bernd van der Loo ◽  
Tamara Kovacevic ◽  
Christiane Brockes ◽  
Valentin Rousson ◽  
...  
Keyword(s):  
Peripheral Arterial Disease ◽  
Brachial Artery ◽  
Intima Media Thickness ◽  
Arterial Disease ◽  
Lipid Lowering ◽  
Control Group ◽  
High Dose ◽  
Atorvastatin Group ◽  
Local Progression ◽  
Peripheral Arterial

SummaryBeneficial effects of aggressive lipid-lowering with high-dose atorvastatin (80 mg/day) have been demonstrated in patients with coronary and cerebrovascular disease. The impact of such a therapy in patients with peripheral arterial disease (PAD) is less known so far. Here we studied the effects of high-dose atorvastatin on brachial artery endothelial function, common carotid intima-media thickness (IMT) and local progression of PAD in these patients. One hundred of 500 patients screened with documented PAD were randomly assigned to receive 80 mg of atorvastatin daily for six months or to continue on conventional medical treatment. Ninety-six percent of patients in the control group were on standard statin treatment. High resolution B-mode ultrasonography was used to study brachial artery flowmediated dilation (FMD), IMT and ankle-brachial index (ABI) at baseline and at six months. FMD and IMT at baseline and at six months were 4.1 (0.06–8.6) versus 5.0 (0.76 vs. 8.1) %, p=0.96, and 0.76 (0.66–0.82) versus 0.73 (0.63–0.81) mm, p=0.41, respectively, in the atorvastatin group, and 2.66 (-1.9 – 6.9) versus 3.65 (0.0–8.6)%, p=0.02, and 0.78 (0.71–0.90) versus 0.77 (0.70–0.90) mm, p=0.48,in the control group. ABI at baseline and at six months was not different in either group. LDL cholesterol was reduced from 2.53 (2.21–3.28) to 1.86 (1.38–2.29) mM (p<0.0001) in the atorvastatin group, whereas levels remained stable in the control group [2.38 (1.94–3.16) vs.2.33 (1.82–2.84) mM, p=0.61]. Major adverse cardiovascular events occurred in 2.1% in the atorvastatin group and 1.9% in the control group (p= 0.61). In conclusion, in this pilot trial aggressive lipid-lowering with 80 mg of atorvastatin daily for six months had no effect on brachial artery FMD in patients with PAD. IMT andABI were also similar in patients with and without high-dose atorvastatin at six months.

Abstract 198: Oxidative Stress Mediates the Augmented Muscle Mechanoreflex in Peripheral Arterial Disease Patients

Hypertension ◽  
2012 ◽  
Vol 60 (suppl_1) ◽  
Author(s):  
Matthew D Muller ◽  
Rachel C Drew ◽  
Cheryl A Blaha ◽  
Jessica L Mast ◽  
Jian Cui ◽  
...  
Keyword(s):  
Ascorbic Acid ◽  
Peripheral Arterial Disease ◽  
Plantar Flexion ◽  
Limb Ischemia ◽  
Arterial Disease ◽  
High Dose ◽  
Dependent Manner ◽  
Low Intensity ◽  
Peripheral Arterial ◽  
Change In Mean

Background Exaggerated blood pressure (BP) responses to dynamic exercise predict cardiovascular mortality in peripheral arterial disease (PAD) patients. However, the underlying mechanisms are unclear and no attempt has been made to attenuate this response using antioxidants. Methods Three physiological studies were conducted in PAD patients and controls. In Protocol 1, subjects underwent four minutes of low-intensity (0.5-2.0 kg), rhythmic plantar flexion in the supine posture. In Protocol 2, PAD patients received high dose ascorbic acid intravenously prior to exercise. In Protocol 3, involuntary exercise was conducted via electrical stimulation of the tibial nerve. The primary outcome measure was the change in mean arterial pressure (ΔMAP) during the first 20 seconds of exercise (i.e. when mechanoreceptors within skeletal muscle activate the sympathetic nervous system). Results Compared to controls, PAD patients had significantly greater ΔMAP during plantar flexion, particularly at 0.5 kg of the most affected leg (11±2 vs. 2±1 mmHg) as well as the least affected leg (7±1 vs. 1±1 mmHg). This augmented response occurred before the onset of claudication pain and was attenuated by ∼50% (i.e. 6 mmHg) in the presence of ascorbic acid. Electrically evoked exercise also elicited larger hemodynamic changes in the PAD patients compared to controls. Further, the ΔMAP during 0.5 kg plantar flexion inversely correlated with the ankle-brachial index, indicating that patients with more severe resting limb ischemia had a larger BP response to exercise. Conclusions The BP response to low intensity exercise was enhanced in PAD. Chronic limb ischemia may sensitize muscle afferents and potentiate the autonomic response to muscle contraction in a dose-dependent manner.

Sign in / Sign up

Export Citation Format

Share Document